AI Article Synopsis
- Sexual functioning is essential for overall human well-being, and female sexual dysfunction (FSD) can significantly impact quality of life.
- The FDA recently approved flibanserin (Addyi) for treating female hypoactive sexual desire disorder (HSDD), which is the most common type of FSD, despite ongoing controversies regarding its effectiveness and safety.
- Flibanserin acts as a multifaceted serotonin agonist and antagonist, showing promise in treating HSDD but has a notable range of side effects that warrant careful consideration.
Article Abstract
Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD) adversely affects quality of life and general well-being. The Food and Drug Administration recently approved flibanserin, for treatment of female hypoactive sexual desire disorder (HSDD), regarded as the most common FSD, amid great controversy. A novel multifunctional serotonin agonist and antagonist, flibanserin, has been shown to be efficacious in treating HSDD but with a rather tenacious side effect profile. We review this interesting drug in its entirety. Data for the article were collected by reviewing articles on PubMed, the drug (Addyi) website, and related websites on the internet.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198608 | PMC |
| http://dx.doi.org/10.4103/ipj.ipj_20_16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuro-immunobiology and treatment assessment in a mouse model of anti-NMDAR encephalitis.
Brain
December 2024
Neuroimmunology Program, Fundació Clínic per la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer (FCRB-IDIBAPS), Barcelona 08036, Spain.
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a disorder mediated by autoantibodies against the GluN1 subunit of NMDAR. It occurs with severe neuropsychiatric symptoms that often improve with immunotherapy. Clinical studies and animal models based on patients' antibody transfer or NMDAR immunization suggest that the autoantibodies play a major pathogenic role.
View Article and Find Full Text PDFTakotsubo Cardiomyopathy in Epilepsy: A Systematic insight into the Existing Literature from 2000-2023.
Pak J Med Sci
December 2024
Professor Asif Bashir, Punjab Institute of Neurosciences, Lahore, Punjab, Pakistan.
Background & Objective: Takotsubo cardiomyopathy (TCM), manifests as left ventricular dysfunction triggered by physical or emotional stress. It leads to higher morbidity in epileptic patients and can progress to complications. To find out the correlation between Takotsubo cardiomyopathy and epilepsy and to investigate pathophysiology and associated types of epilepsy.
View Article and Find Full Text PDFImpact of a Single Session of Hybrid Carbon Dioxide 10600 Nanometer and 1540 Nanometer Laser With Platelet-Rich Plasma Treatment in the Genital Area to Treat Female Sexual Dysfunction: A Pilot Study.
Cureus
December 2024
Department of Aesthetic and Anti-Aging Medicine, Central Medica Quirurgica, Mazatlan, MEX.
Background Female sexual dysfunction (FSD) affects a significant portion of the female population, negatively impacting quality of life. New therapeutic approaches, such as the combination of laser therapy and platelet-rich plasma (PRP), are being explored as potential treatments to enhance sexual function in affected women. Methods This original study involved 23 women aged 37 to 72, all diagnosed with varying degrees of FSD (mild, moderate, severe).
View Article and Find Full Text PDFFemale Pelvic Conditions: Urinary Incontinence.
FP Essent
December 2024
Menominee Tribal Clinic, Keshena, WI.
Urinary incontinence is the involuntary loss of urine. It is a prevalent and bothersome condition in females, with subtypes including stress, urge, mixed stress/urge, and overflow. Evaluation begins with a history to identify symptoms of the different subtypes and information about comorbid conditions, incontinence frequency and severity, and effect on quality of life.
View Article and Find Full Text PDF[Bladder dysfunction in patients with stages I-III of Parkinson's disease].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Objective: To evaluate bladder dysfunction (BD) and its relationship with Parkinson's disease (PD) symptoms and dopaminergic therapy.
Material And Methods: One hundred and thirteen patients with PD of I-III H&Y stages were examined using the following scales: IPSS, including irritative and obstructive symptom indices, UPDRS I-IV, Sch&En, PDQ-39, BDI, STAI, PFS-16, GDSS, GSRS, MMSE, FAB and NMSQ.
Results: Most of the patients (89.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!